SCM
RPRX icon

Stevens Capital Management’s Royalty Pharma RPRX Stock Holding History

Stevens Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-13,365
Closed -$375K – 350
2023
Q4 		$375K Buy
+13,365
New +$367K 0.09% 179

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Stevens Capital Management's RPRX Position: Q1 2024 in Review

Stevens Capital Management sold out of Royalty Pharma (RPRX) in Q1 2024, closing a stake of 13,365 shares — an estimated $375K sold.

Stevens Capital Management first reported a position in RPRX in Q4 2023 and held it in 1 quarter. The position peaked at $375K in Q4 2023. 378 funds tracked by Wall St. Rank hold RPRX as of Q1 2024.

  • Stevens Capital Management reported no remaining Royalty Pharma position as of Q1 2024 after selling out during the quarter.
  • Stevens Capital Management sold 13,365 Royalty Pharma shares in Q1 2024, an estimated $375K.
  • Stevens Capital Management first reported a position in Royalty Pharma in Q4 2023 and held it in 1 quarter.
  • Stevens Capital Management's Royalty Pharma position peaked at $375K in Q4 2023.
  • 378 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2024.

Based on Stevens Capital Management's 13F filing for Q1 2024, filed 8 May 2024.